Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ELI LILLY AND COMPANY

(LLY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Lilly to Supply the EU and EEA with Up to 220,000 Doses of Bamlanivimab

09/23/2021 | 06:04am EDT

AbCellera Biologics Inc. announced that the European Commission (EC) and Eli Lilly and Company (Lilly) have entered into a Joint Procurement Agreement to supply up to 220,000 doses of bamlanivimab together with etesivimab to treat confirmed COVID-19 in patients aged 12 years and older that do not require supplemental oxygen for COVID-19 and who are at increased risk of progressing to severe COVID-19. The agreement helps to provide access to treatments by enabling participating countries in the European Union (EU) and European Economic Area (EEA) to purchase the products directly from Lilly following national approval for emergency use or marketing authorization at the EU level. In the U.S., bamlanivimab alone and together with etesevimab have been used to treat more than 535,000 patients, potentially keeping more than 25,000 patients out of the hospital and saving more than 10,000 lives. The Emergency Use Authorization (EUA) for bamlanivimab together with etesevimab in the U.S. was recently expanded to include post-exposure prophylaxis to prevent COVID-19. Pseudovirus and authentic virus studies demonstrate that bamlanivimab and etesevimab together retain neutralization activity against variants currently in circulation in many countries, including Delta and Alpha. Based on the high transmissibility of the Delta variant, currently over 95% of new COVID-19 infections in the EU/EEA have been identified as being caused by the Delta variant.


ę S&P Capital IQ 2021
All news about ELI LILLY AND COMPANY
10/26Eli Lilly Reports Higher Third-Quarter Results, Raises 2021 Forecast to Reflect Increas..
MT
10/26GLOBAL MARKETS LIVE : Michelin, Facebook, UBS, Tesla, Volvo...
10/26Eli Lilly Intends to Complete US Marketing Application Submission for Alzheimer's Drug ..
MT
10/26Eli Lilly Alzheimer's Programs Head in Different Directions
DJ
10/26Health Care Stocks Edge Higher Premarket Tuesday
MT
10/26Eli Lilly, Pfizer Halt Program for Osteoarthritis Pain Drug
MT
10/26Lilly kicks off application for Alzheimer's drug U.S. approval, ups outlook
RE
10/26WALL STREET STOCK EXCHANGE : Are companies fooling themselves on inflation?
10/26Lilly Cuts Income Targets, Lifts Sales Forecast For FY21
MT
10/26Lilly Reports Robust Third-Quarter 2021 Financial Results as Pipeline Success Strengthe..
PU
More news
Analyst Recommendations on ELI LILLY AND COMPANY
More recommendations
Financials (USD)
Sales 2021 27 373 M - -
Net income 2021 6 145 M - -
Net Debt 2021 11 912 M - -
P/E ratio 2021 38,3x
Yield 2021 1,35%
Capitalization 225 B 225 B -
EV / Sales 2021 8,66x
EV / Sales 2022 8,39x
Nbr of Employees 35 000
Free-Float 99,8%
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Last Close Price 248,44 $
Average target price 269,42 $
Spread / Average Target 8,45%
EPS Revisions
Managers and Directors
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Diogo Rau Senior VP, Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
ELI LILLY AND COMPANY47.15%225 231
JOHNSON & JOHNSON5.32%431 938
ROCHE HOLDING AG15.61%338 364
NOVO NORDISK A/S59.69%243 351
PFIZER, INC.17.22%241 929
MERCK & CO., INC.-0.17%206 712